Aquestive Therapeutics is trading 12.18% up now at $4.42 after its needle-free Anaphylm epinephrine film passed usability and drug-absorption studies, clearing a key FDA hurdle.
- The development strengthens Anaphylm’s path toward regulatory resubmission and potential approval, making it the clear company-specific catalyst for the pre-market jump.
- Investors await second-quarter results and a business update after market close on August 11, 2026.